Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.

Also called NCT03499639

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 110 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03499639
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03499639. Allocation not applicable; no masking; primary purpose treatment. Start 2018-05-01 (actual); primary completion 2018-08-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney Disease
Condition
End-stage Renal Disease
Condition
HCV Coinfection
Intervention (Drug)
Ombitasvir / Paritaprevir / Ritonavir /Ribavirin Oral Tablet
Lead sponsor
Assiut University (class: other)
Collaborator
Sohag University (class: other)
Collaborator
South Valley University (class: other)

Record details

Record id
cardio:ct-nct03499639
Content hash
22499048e5395b47af94661ba4d2b5b76c106377c57203d33aaa8dc0678e7e5d